Skip to content

Impact of Hormonal Contraceptive on Heart Health, Metabolism, and Weight.

Cardiovascular, Metabolic, and Anthropometric Effects of Using Contraceptives Containing Estradiol Valerate and Nomegestrol Acetate.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-10c6py3j
Enrollment
40
Registered
2026-07-02
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

This is a single arm clinical trial in which forty women will receive a combined oral contraceptive containing nomegestrol acetate with estradiol and will be evaluated before and after use using labor

Sponsors

Universidade de Gurupi
Lead Sponsor
Universidade de Gurupi
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 49 Years

Inclusion criteria

Inclusion criteria: Women of reproductive age; over 18 years old; classified as class 1 or 2 according to WHO eligibility criteria

Exclusion criteria

Exclusion criteria: Women under 18 years of age or postmenopausal; with absolute or relative contraindications to the use of estrogens

Design outcomes

Primary

MeasureTime frame
It is expected to find that blood pressure levels and glycemic and lipid profiles as well as anthropometric measurements will remain stable

Secondary

MeasureTime frame
It is expected that modifying factors will have an influence, such as level of physical activity (IPAQ); smoking and alcohol consumption; adherence to the contraceptive method;It is expected that participants will experience a high degree of satisfaction with the contraceptive method and a desire to continue using it after 6 and 12 months

Countries

BR

Contacts

Public ContactFabiana Anjos

Universidade de Gurupi- UNIRG

fcqsa77@gmail.com+55-063-981229877

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Aug 10, 2026